Egis Pharmaceuticals

Profit Statement 2010 2011 2012
Sales HUF mil 118,915 128,939 132,825
Gross Profit HUF mil 66,709 72,106 75,668
EBITDA HUF mil 23,809 25,609 30,536
EBIT HUF mil 15,512 16,302 20,436
Financing Cost HUF mil 423 83.0 46.0
Pre-Tax Profit HUF mil 17,755 15,676 20,288
Net Profit HUF mil 16,783 13,585 18,531
Balance Sheet 2010 2011 2012
Total Assets HUF mil 174,542 190,720 208,238
Non-Current Assets HUF mil 75,028 78,503 82,248
Current Assets HUF mil 99,514 112,217 125,990
Working Capital HUF mil 49,188 51,578 50,982
Shareholders' Equity HUF mil 149,122 161,639 179,490
Liabilities HUF mil 25,420 29,081 28,748
Total Debt HUF mil 3,210 3,176 2,908
Net Debt HUF mil -14,763 -32,381 -43,021
Ratios 2010 2011 2012
ROE % 11.9 8.74 10.9
ROCE % 14.4 10.7 14.1
Gross Margin % 56.1 55.9 57.0
EBITDA Margin % 20.0 19.9 23.0
EBIT Margin % 13.0 12.6 15.4
Net Margin % 14.1 10.5 14.0
Net Debt/EBITDA -0.620 -1.26 -1.41
Net Debt/Equity -0.099 -0.200 -0.240
Cost of Financing % 13.3 2.60 1.51
Cash Flow 2010 2011 2012
Total Cash From Operations HUF mil 14,379 26,527 26,342
Total Cash From Investing HUF mil -18,702 -15,052 -14,896
Total Cash From Financing HUF mil -942 -1,123 -1,074
Net Change In Cash HUF mil -5,265 10,352 10,372
Cash Conversion Cycle days 226 224 207
Cash Earnings HUF mil 25,080 22,892 28,631
Free Cash Flow HUF mil -4,323 11,475 11,446

Get all company financials in excel:

Download Sample   $19.99

summary Unit 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
income statement                          
Sales HUF mil             110,800 117,176 109,192 116,142 118,915    
Gross Profit HUF mil             59,692 54,322 57,554 64,350 66,709    
EBIT HUF mil             15,965 7,789 8,597 14,040 15,512    
Net Profit HUF mil             16,883 7,622 12,044 13,751 16,783    
ROE %             18.1 7.27 10.6 10.9 11.9    
EBIT Margin %             14.4 6.65 7.87 12.1 13.0    
Net Margin %             15.2 6.50 11.0 11.8 14.1    
balance sheet                          
Total Assets HUF mil             116,388 125,842 139,926 157,904 174,542    
Non-Current Assets HUF mil             52,168 58,019 63,700 68,948 75,028    
Current Assets HUF mil             64,220 67,823 76,226 88,956 99,514    
Shareholders' Equity HUF mil             101,541 108,049 119,229 132,757 149,122    
Liabilities HUF mil             14,847 17,793 20,697 25,147 25,420    
Non-Current Liabilities HUF mil             1,312 1,742 3,606 4,081 4,205    
Current Liabilities HUF mil             13,535 16,051 17,091 21,066 21,215    
Net Debt/EBITDA             -0.199 -0.492 -0.109 -0.912 -0.620    
Net Debt/Equity             -0.043 -0.066 -0.015 -0.150 -0.099    
Cost of Financing % ...           12.3 309 54.2 61.8 13.3    
cash flow                          
Total Cash From Operations HUF mil ... ... ...       13,345 15,556 15,308 22,729 14,379    
Total Cash From Investing HUF mil ... ... ...       -10,268 -12,217 -19,642 -3,042 -18,702    
Total Cash From Financing HUF mil ... ... ...       -2,941 -4.00 785 -1,187 -942    
Net Change In Cash HUF mil ... ... ...       136 3,335 -3,549 18,500 -5,265    
valuation                          
Number Of Shares mil             7.79 7.79 7.79 7.79 7.79    
Share Price HUF             30,000 22,990 11,270 19,600 22,300    
Earnings Per Share (EPS) HUF             2,169 979 1,547 1,766 2,156    
Book Value Per Share HUF             13,042 13,878 15,314 17,051 19,153    
Price/Earnings (P/E)             13.8 23.5 7.29 11.1 10.3    
Price/Book Value (P/BV)             2.30 1.66 0.736 1.15 1.16    
Earnings Per Share Growth % ...           51.3 -54.9 58.0 14.2 22.0    
Book Value Per Share Growth % ...           18.8 6.41 10.3 11.3 12.3    
income statement Unit 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
income statement                          
Sales HUF mil             110,800 117,176 109,192 116,142 118,915    
Cost of Goods & Services HUF mil             51,108 62,854 51,638 51,792 52,206    
Gross Profit HUF mil             59,692 54,322 57,554 64,350 66,709    
EBITDA HUF mil             21,996 14,573 16,696 21,851 23,809    
Depreciation HUF mil             6,031 6,784 8,099 7,811 8,297    
EBIT HUF mil             15,965 7,789 8,597 14,040 15,512    
Financing Cost HUF mil             193 2,623 1,093 1,874 423    
Extraordinary Cost HUF mil             -3,390 -2,698 -5,232 -2,359 -2,666    
Pre-Tax Profit HUF mil             19,162 7,864 12,736 14,525 17,755    
Tax HUF mil             2,278 242 692 774 972    
Minorities HUF mil             0 0 0 0 0    
Net Profit HUF mil             16,883 7,622 12,044 13,751 16,783    
growth rates                          
Total Revenue Growth % ...           18.3 5.75 -6.81 6.36 2.39    
EBITDA Growth % ...           49.1 -33.7 14.6 30.9 8.96    
EBIT Growth % ...           62.2 -51.2 10.4 63.3 10.5    
Pre-Tax Profit Growth % ...           54.9 -59.0 62.0 14.0 22.2    
Net Profit Growth % ...           51.3 -54.9 58.0 14.2 22.0    
ratios                          
ROE %             18.1 7.27 10.6 10.9 11.9    
ROCE % ...           18.8 7.97 11.9 12.9 14.4    
Gross Margin %             53.9 46.4 52.7 55.4 56.1    
EBITDA Margin %             19.9 12.4 15.3 18.8 20.0    
EBIT Margin %             14.4 6.65 7.87 12.1 13.0    
Net Margin %             15.2 6.50 11.0 11.8 14.1    
Cost of Financing % ...           12.3 309 54.2 61.8 13.3    
Net Debt/EBITDA             -0.199 -0.492 -0.109 -0.912 -0.620    
balance sheet Unit 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
balance sheet                          
Non-Current Assets HUF mil             52,168 58,019 63,700 68,948 75,028    
Property, Plant & Equipment HUF mil             40,970 45,275 51,513 57,189 63,508    
Intangible Assets HUF mil             678 696 3,865 4,286 4,089    
Current Assets HUF mil             64,220 67,823 76,226 88,956 99,514    
Inventories HUF mil             29,662 29,866 33,790 38,957 38,768    
Receivables HUF mil             20,960 17,874 23,564 19,830 30,176    
Cash & Cash Equivalents HUF mil             4,952 8,287 4,738 23,072 17,973    
Total Assets HUF mil             116,388 125,842 139,926 157,904 174,542    
Shareholders' Equity HUF mil             101,541 108,049 119,229 132,757 149,122    
Of Which Minority Interest HUF mil             0 0 0 0 0    
Liabilities HUF mil             14,847 17,793 20,697 25,147 25,420    
Non-Current Liabilities HUF mil             1,312 1,742 3,606 4,081 4,205    
Long-Term Debt HUF mil             0 1,068 2,825 3,029 2,989    
Current Liabilities HUF mil             13,535 16,051 17,091 21,066 21,215    
Short-Term Debt HUF mil             583 48.0 95.0 111 221    
Trade Payables HUF mil             8,294 8,905 16,244 19,649 19,756    
Equity And Liabilities HUF mil             116,388 125,842 139,926 157,904 174,542    
growth rates                          
Total Asset Growth % ...           14.5 8.12 11.2 12.8 10.5    
Shareholders' Equity Growth % ...           18.8 6.41 10.3 11.3 12.3    
Net Debt Growth % ...           93.2 64.1 -74.6 996 -25.9    
Total Debt Growth % ...           -77.2 91.4 162 7.53 2.23    
ratios                          
Total Debt HUF mil             583 1,116 2,920 3,140 3,210    
Net Debt HUF mil             -4,369 -7,171 -1,818 -19,932 -14,763    
Working Capital HUF mil             42,328 38,835 41,110 39,138 49,188    
Capital Employed HUF mil             94,496 96,854 104,810 108,086 124,216    
Net Debt/Equity             -0.043 -0.066 -0.015 -0.150 -0.099    
Cost of Financing % ...           12.3 309 54.2 61.8 13.3    
cash flow Unit 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
cash flow                          
Net Profit HUF mil             16,883 7,622 12,044 13,751 16,783    
Depreciation HUF mil             6,031 6,784 8,099 7,811 8,297    
Non-Cash Items HUF mil ... ... ...       -5,110 -2,343 -2,560 -805 -651    
Change in Working Capital HUF mil ... ... ...       -4,460 3,493 -2,275 1,972 -10,050    
Total Cash From Operations HUF mil ... ... ...       13,345 15,556 15,308 22,729 14,379    
Capital Expenditures HUF mil ... ... ...       -10,447 -12,454 -13,680 -14,070 -14,508    
Other Investments HUF mil ... ... ...       179 237 -5,962 11,028 -4,194    
Total Cash From Investing HUF mil ... ... ...       -10,268 -12,217 -19,642 -3,042 -18,702    
Issuance Of Debt HUF mil ... ... ...       -1,972 533 1,804 220 70.0    
Total Cash From Financing HUF mil ... ... ...       -2,941 -4.00 785 -1,187 -942    
Net Change In Cash HUF mil ... ... ...       136 3,335 -3,549 18,500 -5,265    
ratios                          
Days Sales Outstanding days             69.0 55.7 78.8 62.3 92.6    
Days Sales Of Inventory days             212 173 239 275 271    
Days Payable Outstanding days             59.2 51.7 115 138 138    
Cash Conversion Cycle days             222 177 203 198 226    
Cash Earnings HUF mil             22,915 14,406 20,143 21,562 25,080    
Cash Earnings Per Share HUF             2,943 1,850 2,587 2,769 3,221    
Price/Cash Earnings (P/CE)             10.2 12.4 4.36 7.08 6.92    
Free Cash Flow HUF mil ... ... ...       3,077 3,339 -4,334 19,687 -4,323    
other data Unit 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
other data                          
ROA %             15.5 6.29 9.06 9.23 10.1    
Gross Margin %             53.9 46.4 52.7 55.4 56.1    
Effective Tax Rate %             11.9 3.08 5.43 5.33 5.47    
Capital Expenditures (As % of Sales) % ... ... ...       9.43 10.6 12.5 12.1 12.2    

Get all company financials in excel:

Download Sample   $19.99

EGIS Pharmaceuticals Plc (Egis) is a Hungary-based pharmaceutical company focused on the research, development and commercialization of pharmaceuticals and active pharmaceutical ingredients (API). The company is principally focused on the development of human pharmaceuticals for the treatment of cardiovascular, central nervous system, respiratory and digestive system disorders. The company sells its products in several countries across the world through its subsidiary companies network. EGIS predominantly operates in the Eastern Europe and has presence across countries such as Russia, Ukraine, the Czech Republic, Poland, Romania and Slovakia. The company is headquartered in Budapest, Hungary.

More Companies in Hungarian Pharmaceutical Sector